PREGNANCY LABELING CATEGORY REVISIONS UNDER CONSIDERATION
PREGNANCY LABELING CATEGORY REVISIONS UNDER CONSIDERATION by FDA, according to Metabolism and Endocrine Drug Products Division Director Solomon Sobel, MD. Speaking at an FDA-sponsored conference on regulated products and pregnant women on Nov. 7-8 in Crystal City, Va., Sobel reported that an ad hoc panel of pharmacologists and toxicologists has been active for about one year developing recommendations for FDA on whether changes to the current system are needed and how they should be accomplished. The panel's recommendations would require approval by FDA's office and division directors and would go through a formal notice and comment period.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth